<DOC>
	<DOCNO>NCT00294619</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety profile new weekly administer growth hormone preparation compare placebo adult growth hormone deficiency .</brief_summary>
	<brief_title>Treatment Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male female least 23 year 70 year age GHD either adult onset ( AO ) Childhood onset ( CO ) , either idiopathic secondary pituitary disease Confirmed diagnosis GHD define IGF1 SDS â‰¤ 1 screen No exposure rhGH within last 6 month Patients adequate adrenal function , confirm ACTH stimulation test screening ; Patients know secondary hypoadrenalism adequate glucocorticoid replacement therapy If applicable , hormone replacement therapy hormone deficiency , adequate stable least 3 month study entry Women childbearing potential use reliable method contraception screen willing use throughout study A negative serum pregnancy test require screening female childbearing potential . History malignancy cranial tumor leukemia cause GHD fully treat basal cell carcinoma Evidence active malignancy Evidence growth pituitary adenoma intracranial tumor within last 12 month , patient without MRI CT data confirm tumor stability within last 12 month Significant hepatic dysfunction Chronic renal impairment Clinically significant pulmonary , cardiac , hepatic , renal , neuromuscular disease PraderWilli syndrome Acute severe illness last 6 month Benign intracranial hypertension Active Cushing 's syndrome within last 12 month Uncontrolled hypertension Patients overt diabetes mellitus evidence persistent impair glucose tolerance Severe psychiatric disease patient understand objective method study patient current alcohol abuse Pregnancy lactation Known hypersensitivity ingredient study drug Inability undergo scan dualenergy X ray absorptiometry ( DXA ) due body weight 130 kg situ internal external device know interfere DXA scan Weight reduce drug appetite suppressant Anabolic steroid gonadal steroid replacement therapy within 2 month study entry Methylphenidate within 2 month study entry Systemic corticosteroid replacement dos within 3 month study entry . History noncompliance medication , uncooperativeness drug abuse Patients participate another study parallel , within 6 month prior study entry , previous participation study Patients able comply study protocol reason .</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Growth hormone deficiency</keyword>
</DOC>